
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
A roundup of the key stories across genitourinary cancers from the second quarter of 2026.
The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from new FDA approvals to pivotal phase 3 data presented at major scientific meetings. Advances in bladder, prostate, and kidney cancer expanded treatment options in both the adjuvant and perioperative settings while highlighting the growing role of biomarker-guided care and combination strategies.





